2022
Associations of the serum kynurenine pathway metabolites with P50 auditory gating in non-smoking patients with first-episode schizophrenia
Yang Q, Zhang Y, Yang K, Niu Y, Fan F, Chen S, Luo X, Tan S, Wang Z, Tong J, Yang F, Li C, Tan Y. Associations of the serum kynurenine pathway metabolites with P50 auditory gating in non-smoking patients with first-episode schizophrenia. Frontiers In Psychiatry 2022, 13: 1036421. PMID: 36339840, PMCID: PMC9632432, DOI: 10.3389/fpsyt.2022.1036421.Peer-Reviewed Original ResearchFirst-episode schizophreniaP50 auditory gatingNon-smoking patientsHealthy controlsAuditory gatingSerum kynurenineSerum levelsS2/S1 ratioAcid levelsKynurenine pathway metabolitesFirst-episode patientsNegative Syndrome ScaleKynurenine acidEpisode patientsNeuroactive metabolitesKynurenine pathwayPatientsS1 ratioSyndrome ScaleCognitive impairmentS1-S2SchizophreniaPathway metabolitesS1 amplitudeKynurenineLinear Mixed Model Analysis of Polygenic Hazard Score on Verbal Memory Decline in Alzheimer’s Disease
Wang K, Xu C, Theeke LA, Xiao D, Luo X, Xie C, Initiative A. Linear Mixed Model Analysis of Polygenic Hazard Score on Verbal Memory Decline in Alzheimer’s Disease. Nursing Research 2022, 72: 66-73. PMID: 36097266, DOI: 10.1097/nnr.0000000000000623.Peer-Reviewed Original ResearchConceptsRey Auditory Verbal Learning TestAuditory Verbal Learning TestMini-Mental State Examination scoreVerbal Learning TestVerbal memory declineState Examination scoreAPOE ε4 alleleVerbal memory lossDisease Neuroimaging InitiativeVerbal memoryCognitive measuresLearning TestLinear mixed modelsMemory declineMild cognitive impairmentExamination scoresLongitudinal effectsLinear mixed model analysisBaseline Mini-Mental State Examination scorePolygenic hazard scoreCognitive dysfunctionCognitive impairmentMixed model analysisAlzheimer's Disease Neuroimaging InitiativeAlzheimer's diseaseThe relationship between TLR4/NF-κB/IL-1β signaling, cognitive impairment, and white-matter integrity in patients with stable chronic schizophrenia
Li H, Chen W, Gou M, Li W, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Pan S, Li N, Luo X, Zhang P, Huang J, Tian L, Li CR, Tan Y. The relationship between TLR4/NF-κB/IL-1β signaling, cognitive impairment, and white-matter integrity in patients with stable chronic schizophrenia. Frontiers In Psychiatry 2022, 13: 966657. PMID: 36051545, PMCID: PMC9424630, DOI: 10.3389/fpsyt.2022.966657.Peer-Reviewed Original ResearchStable chronic schizophreniaNF-κB/ILWhite matter integrityHealthy controlsMATRICS Consensus Cognitive BatteryFractional anisotropyChronic schizophreniaCortical thicknessCognitive impairmentInnate immunityCognitive functionToll-like receptor 4Higher TLR4 levelsLevels of TLR4Subcortical gray matter volumesWhite matter fractional anisotropyNegative Syndrome ScaleGray matter volumeTLR4 expressionTLR4 levelsWhite matter microstructureReceptor 4Cognitive deteriorationConsensus Cognitive BatteryLPS stimulationSerum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness
Lin C, Gou M, Pan S, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Luo X, Li CR, Zhang P, Huang J, Hong L, Tan Y. Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness. Neuroscience Letters 2022, 788: 136826. PMID: 35944595, DOI: 10.1016/j.neulet.2022.136826.Peer-Reviewed Original ResearchConceptsBrain cortical thicknessCognitive impairmentCognitive deficitsGray matter thicknessSchizophrenia (MATRICS) Consensus Cognitive BatteryAttention/vigilanceConsensus Cognitive BatteryCortical thicknessSerum Hcy levelsFirst-episode patientsHealthy controlsHigh homocysteineWorking memoryHcy levelsCognitive batteryNegative Symptom ScaleCognitive functionTreatment researchHigh-resolution magnetic resonance imagingSymptom ScaleSandwich enzyme-linked immunosorbentSchizophreniaHigher cortical thicknessImpairmentEnzyme-linked immunosorbent
2020
Associations between brain‐derived neurotrophic factor and cognitive impairment in panic disorder
Wang W, Liu Y, Luo S, Guo X, Luo X, Zhang Y. Associations between brain‐derived neurotrophic factor and cognitive impairment in panic disorder. Brain And Behavior 2020, 10: e01885. PMID: 33047489, PMCID: PMC7749616, DOI: 10.1002/brb3.1885.Peer-Reviewed Original ResearchConceptsBDNF Met/Met genotypeMet/Met genotypeLower BDNF plasma levelsPanic disorderCognitive impairmentMet genotypeMontreal Cognitive AssessmentStroop interferenceVerbal learningNeurocognitive measuresCognitive performanceBDNF plasma levelsMoCA dataCognitive AssessmentAnxiety ScaleBDNF Val66Met polymorphismVal/ValPanic symptomsLower scoresPD patientsHamilton Anxiety ScaleProcessing domainPlasma levelsHealthy controlsModerate positive correlationPsychometric properties of the MATRICS Consensus Cognitive Battery (MCCB) in Chinese patients with major depressive disorder
Liang S, Yu W, Ma X, Luo S, Zhang J, Sun X, Luo X, Zhang Y. Psychometric properties of the MATRICS Consensus Cognitive Battery (MCCB) in Chinese patients with major depressive disorder. Journal Of Affective Disorders 2020, 265: 132-138. PMID: 32090734, DOI: 10.1016/j.jad.2020.01.052.Peer-Reviewed Original ResearchConceptsMajor depression disorderMATRICS Consensus Cognitive BatteryMDD patientsCognitive impairmentChinese patientsConsensus Cognitive BatteryBipolar disorderHamilton Depression Rating Scale-17Cognitive AssessmentChinese MDD patientsMajor depressive disorderSeverity of symptomsMontreal Cognitive AssessmentConcurrent validityMild cognitive impairmentCognitive batteryPsychometric propertiesGood concurrent validityMedication treatmentDepressive disorderHealthy controlsGood internal consistencyDepressive symptomsDepression disorderPatients
2019
Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia
Xie T, Li Q, Luo X, Tian L, Wang Z, Tan S, Chen S, Yang G, An H, Yang F, Tan Y. Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia. Cognitive Neurodynamics 2019, 13: 357-365. PMID: 31354881, PMCID: PMC6624222, DOI: 10.1007/s11571-019-09530-3.Peer-Reviewed Original ResearchAttention/vigilanceSpeed of processingTotal antioxidant statusFirst-episode drug-naïve patientsDrug-naïve patientsCognitive impairmentCognitive deficitsSchizophrenia (MATRICS) Consensus Cognitive BatteryMCCB total scoreConsensus Cognitive BatteryHealthy controlsAntioxidant statusPlasma total antioxidant statusSex-matched healthy controlsOxidative stressPlasma TAS levelsPathophysiology of schizophreniaCognitive batteryStroop testNegative Syndrome ScaleReactive oxygen species-induced oxidative damageTreatment researchPsychopathological symptomsFEDN patientsHealthy subjects
2016
BDNF Polymorphisms Are Associated With Cognitive Performance in Schizophrenia Patients Versus Healthy Controls.
Zhang XY, Chen da C, Tan YL, Tan S, Luo X, Zuo L, Soares JC. BDNF Polymorphisms Are Associated With Cognitive Performance in Schizophrenia Patients Versus Healthy Controls. The Journal Of Clinical Psychiatry 2016, 77: e1011-8. PMID: 27561148, DOI: 10.4088/jcp.15m10269.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorHealthy controlsCognitive functionBDNF gene variantsCase-control studyBDNF genetic variantsBDNF gene polymorphismPathogenesis of schizophreniaCognitive performanceRBANS total scoreHan Chinese populationBDNF polymorphismVal66Met polymorphismNeurotrophic factorBDNF geneGene polymorphismsCognitive impairmentPatientsPotential associationChinese populationNeuropsychological StatusHan Chinese individualsRepeatable BatterySchizophreniaTotal score
2013
Cognitive Function, Plasma MnSOD Activity, and MnSOD Ala-9Val Polymorphism in Patients With Schizophrenia and Normal Controls
Zhang XY, Chen D, Xiu MH, Yang FD, Tan Y, Luo X, Zuo L, Kosten TA, Kosten TR. Cognitive Function, Plasma MnSOD Activity, and MnSOD Ala-9Val Polymorphism in Patients With Schizophrenia and Normal Controls. Schizophrenia Bulletin 2013, 40: 592-601. PMID: 23588476, PMCID: PMC3984504, DOI: 10.1093/schbul/sbt045.Peer-Reviewed Original ResearchConceptsAla-9Val polymorphismNormal controlsCognitive impairmentMnSOD activityAla allele carriersChronic schizophrenic patientsMitochondrial enzyme manganese superoxide dismutaseNegative Syndrome ScaleEnzyme manganese superoxide dismutaseHealthy controlsManganese superoxide dismutaseAllele carriersExcessive reactive oxygen speciesSchizophrenic patientsSchizophrenic inpatientsSyndrome ScaleCognitive deficitsNeuropsychological StatusCognitive functionPatients' psychopathologyRepeatable BatteryPatientsSchizophreniaTotal scoreReactive oxygen species
2012
Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls
Zhang XY, Chen DC, Xiu MH, Haile CN, Luo X, Xu K, Zhang HP, Zuo L, Zhang Z, Zhang X, Kosten TA, Kosten TR. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Human Genetics 2012, 131: 1187-1195. PMID: 22362486, PMCID: PMC3671849, DOI: 10.1007/s00439-012-1150-x.Peer-Reviewed Original ResearchConceptsBDNF Val66Met polymorphismBDNF levelsRBANS total scoreHealthy controlsSchizophrenic patientsVal66Met polymorphismHippocampal-dependent cognitive functionsCognitive deficitsBrain-derived neurotrophic factor (BDNF) geneTotal scoreBDNF serum levelsBDNF Val66Met gene polymorphismPeripheral BDNF levelsSerum BDNF levelsMet variantNeurotrophic factor geneNegative Syndrome ScaleSerum BDNFSerum levelsPatient groupNormal controlsSchizophrenic inpatientsGene polymorphismsSyndrome ScaleCognitive impairment